

# **Neurocognitive Efficacy of Alternative Gold-Containing Formulations: Traditional Poly-Herbomineral Concoctions and Engineered Catalytic Nanomedicines**

## **I. Executive Summary: The Emerging Dual Landscape of Gold-Based Neurotherapeutics**

Research confirming the cognitive advantages of gold preparations has historically centered on *Suvarnaprashana* (SP), an Ayurvedic pediatric formulation primarily leveraging *Swarna Bhasma* (SB). However, an expert analysis reveals a wider, dual-system landscape of gold-based neurotherapeutics demonstrating cognitive utility: complex traditional poly-herbomineral formulations and modern, engineered catalytic gold nanomedicines (CNM-Au8).

The core finding is that gold's neuroactivity is not restricted to SP. Traditional Ayurvedic texts advocate for alternative compounds such as *Kumarabharana Rasa* and gold-infused *Brahmi Vati*, which combine the foundational *Swarna Bhasma* with potent *Medhya Rasayanas* (nootropic herbs).<sup>1</sup> While these preparations possess strong compositional promise and leverage SB's proven preclinical antioxidant and anxiolytic effects<sup>3</sup>, verifiable clinical data proving gold's incremental cognitive benefit beyond the effects of the powerful herbal components remains absent.<sup>2</sup>

In stark contrast, modern translational research utilizing engineered gold nanocrystals (CNM-Au8) provides robust, high-level clinical evidence. CNM-Au8 functions as a metabolic catalyst, significantly improving the brain's cellular energy production (NAD+/NADH ratio).<sup>5</sup> Phase 2 clinical trials in neurodegenerative disease demonstrate quantified, significant cognitive improvement (measured via SDMT) that correlates directly with anatomical and physiological evidence of neuronal repair and remyelination.<sup>7</sup> This establishes a clear scientific benchmark, affirming that gold, when delivered with high precision, can function as a potent disease-modifying neurotherapeutic.

## **II. Pharmacological Precursor: Swarna Bhasma (SB) and Foundational Neuroactivity**

The foundational gold component utilized in nearly all traditional Indian medicinal concoctions is *Swarna Bhasma* (SB), a highly purified, calcined ash of gold. Understanding SB's intrinsic neuroactivity is essential for assessing the compounds that incorporate it.

## **2.1. Physicochemical Characteristics and Mechanism of Bioavailability**

*Swarna Bhasma* is scientifically characterized not as metallic gold, but as an ancient form of nanomedicine. Modern analysis confirms that SB consists of spherical gold nanoparticles, typically ranging in size from approximately 28–35 nm, with crystallites often measuring around \$45 \text{ }\mu\text{m } 2.8\\$ \text{ nm}^4\$. This nano-scale size is critical for systemic distribution.

The long, multi-step process of *bhasmikarana* (calcination and purification) in traditional Ayurveda, refined over centuries of empirical practice, successfully converts bulk metal into particles small enough to be biologically active. The therapeutic efficacy is predicated on the ability of gold nanoparticles (Au-NPs), usually those smaller than 58 nm, to be absorbed in the small intestine and subsequently cross the Blood-Brain Barrier (BBB).<sup>4</sup> This delivery mechanism allows the gold to reach the central nervous system (CNS) and potentially release active gold ions ( $\text{Au}(\text{I})$ ) in a sustained manner, which is necessary for long-term therapeutic action.<sup>4</sup> The consistency observed in achieving particles capable of CNS access validates the protocols of the traditional preparation as an optimized, albeit ancient, delivery system for neurological targets.

## **2.2. Preclinical Evidence for SB's Core Neuroprotective and Anxiolytic Effects**

Research demonstrates that SB possesses significant neuropharmacological properties, independent of the herbal matrices in which it is usually delivered. It is advocated in classical literature for memory enhancement and improving learning abilities.<sup>3</sup>

A primary mechanism of action is robust antioxidant capacity. SB neutralizes harmful free radicals and combats oxidative stress, a key mechanism underlying various neurodegenerative processes.<sup>4</sup> Studies evaluating biochemical parameters in the blood plasma of treated rats indicated that SB was a potent antioxidant.<sup>3</sup>

Crucially, SB has been shown to restore cognitive function in stress models. In a study involving sleep-deprived rats, SB successfully reverted the induced cognitive deficits. Animals treated with SB showed improved performance in spatial memory tasks, evidenced by an increase in correct arm entries, a decrease in the number of errors, and a decrease in the time required to complete the task.<sup>3</sup>

Beyond cognition, SB also exhibits significant anxiolytic and antidepressant properties.<sup>3</sup> Behavioral assessments using a zebrafish model confirmed these anxiolytic effects, demonstrated by an increase in the average swimming height and the time spent in the upper

zone of the tank.<sup>3</sup> A notable finding from this research was the longevity of the effect; the anxiolytic benefits persisted for over 30 days following the cessation of SB treatment.<sup>3</sup> This prolonged retention of behavioral benefits suggests that SB's impact is not transient, but rather induces stable, long-term protective adaptations within the nervous system, supporting its application in chronic neurological conditions or developmental programs.

### **III. Alternative Traditional Poly-Herbomineral Gold Concoctions**

The user query specifically seeks gold formulations other than *Suvarnaprashana*. Several complex traditional compounds incorporate *Swarna Bhasma* alongside synergistic botanical nootropics (*Medhya Rasayanas*) and other metallic or mineral ashes, aiming for enhanced cognitive outcomes.

#### **3.1. Kumarabharana Rasa (KR): A Comprehensive Nootropic Blend**

*Kumarabharana Rasa* (KR) is a complex poly-herbomineral electuary (*Lehya*) used in *Lehana Karma*, a traditional practice aimed at promoting nutrition, immunity, and overall physical and psychic strength, particularly in infants and children.<sup>1</sup>

The cognitive potential of KR stems from its dense composition, which includes three metallic *Bhasmas*—*Swarna* (Gold), *Rajata* (Silver), and *Pravala* (Coral)—combined with highly regarded herbal nootropics.<sup>1</sup> Key botanical constituents include *Vacha* (*Acorus calamus*), *Ashwagandha* (*Withania somnifera*), and *Haritaki*, processed with extracts (*Swarasa*) of *Brahmi* (*Bacopa monnieri*) and *Guduchi* (*Tinospora cordifolia*).<sup>1</sup>

While the formulation is traditionally intended for broad enhancement of intelligence and mental strength, the available peer-reviewed literature predominantly focuses on non-cognitive indications, such as the management of chronic tonsillitis.<sup>11</sup> Therefore, although the compositional synergy of SB with multiple powerful *Medhya* herbs suggests strong theoretical neurocognitive efficacy, specific clinical trials demonstrating this benefit are currently lacking.

#### **3.2. Brahmi- and Vacha-Containing Gold Concoctions**

Other significant gold-containing compounds strategically integrate SB with specific single-herb nootropics known for their cognitive function enhancement.

##### **3.2.1. Brahmi Vati Gold and Saraswatharishtam with Gold**

Formulations such as *Brahmi Vati Gold* and *Saraswatharishtam with Gold* represent common gold-infused versions of classical preparations. *Brahmi Vati Gold* combines the well-known nootropic effects of *Bacopa monnieri* (Brahmi) with gold (*Swarna Bhasma*).<sup>2</sup> Similarly, *Saraswatharishtam with Gold* utilizes Brahmi alongside other herbs, claiming to enhance

intelligence, increase memory, and serve as an excellent tonic for the mind and nerves.<sup>13</sup>

Manufacturers frequently assert that the inclusion of gold in these preparations, based on traditional use, takes the formulation a step further by enhancing brain function, promoting mental clarity, and providing superiority over the standard non-gold version.<sup>2</sup>

### 3.2.2. The Challenge of Unverified Synergy

While the traditional belief holds that gold, as a *yogavahi* or general rejuvenator, amplifies the effects of the herbs, a critical translational hurdle exists: there are no published clinical studies that comparatively evaluate the cognitive benefits of the gold-infused variants (e.g., *Brahmi Vati Gold*) against the standard herbal formulation (e.g., plain *Brahmi Vati*).<sup>2</sup> The cognitive improvement observed by users of these products may be attributable primarily to the proven pharmacological effects of the potent *Medhya* components, particularly Brahmi and Vacha. Without comparative scientific verification, the claim that gold provides incremental neurocognitive benefit in these specific poly-formulations remains an unproven hypothesis rooted in traditional knowledge.<sup>2</sup>

Table 1 provides a critical comparison of these alternative traditional gold-containing formulations, highlighting the ingredients intended for synergy with gold and the crucial lack of comparative clinical data.

Table 1: Analysis of Traditional Gold-Containing Formulations (Excluding Suvarnaprashana)

Formulation Name	Primary Gold Component	Key Cognitive Synergistic Ingredients	Reported Cognitive Indication/Claim	Level of Supporting Evidence
Kumarabhara na Rasa (KR)	Swarna Bhasma (Gold Calx)	Brahmi, Vacha, Ashwagandha, Guduchi, Rajata Bhasma	Promotes physical and psychic strength; broad spectrum Lehana karma	Compositional Review; Evidence focused on non-cognitive outcomes <sup>1</sup>
Brahmi Vati Gold	Swarna Bhasma (Gold Calx)	Brahmi ( <i>Bacopa monnieri</i> )	Enhance memory, focus, and mental clarity;	Traditional/Product Claims; Explicitly Lacking

			superior to non-gold version	Comparative Clinical Data <sup>2</sup>
<b>Saraswathari shtam with Gold</b>	Swarna (Gold, likely Bhasma)	Brahmi ( <i>Bacopa monnieri</i> )	Enhances intelligence; increases memory; excellent tonic for nerves/mind	Traditional/Product Claims; Cited in reviews of <i>Medhya Rasayanas</i> <sup>13</sup>

## IV. CNM-Au8: A Case Study in Modern Catalytic Gold Nanomedicine

In stark contrast to the traditional formulations, a modern, engineered gold nanomedicine, CNM-Au8, provides the strongest clinical evidence for gold's cognitive utility outside of *Suvarnaprashana* through highly targeted, mechanism-specific trials.

### 4.1. Formulation, Mechanism, and Targeted Metabolic Action

CNM-Au8 is an investigational therapeutic agent developed for neurodegenerative diseases such as Multiple Sclerosis (MS), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS).<sup>5</sup> It is an oral suspension comprising highly uniform, faceted, clean-surfaced gold nanocrystals.<sup>5</sup> The manufacturing precision inherent in this process distinguishes it significantly from the traditional, artisanal production of *Swarna Bhasma*.

CNM-Au8 operates as a first-in-class catalytic therapy. Its fundamental mechanism is the restoration of neuronal health and function by increasing energy production and utilization.<sup>15</sup> The catalytically active nanocrystals specifically target mitochondrial function and the Nicotinamide Adenine Dinucleotide (NAD) pathway.<sup>15</sup> Neurodegenerative conditions are characterized by a decline in brain energy metabolism, notably a decrease in the crucial ratio of  $\text{NAD}^+$  to  $\text{NADH}$ .<sup>14</sup> CNM-Au8 dose-dependently increases this  $\text{NAD}^+/\text{NADH}$  ratio, enabling neuroprotection and remyelination by improving neuronal and glial resilience to disease stressors.<sup>16</sup> This proven molecular action of correcting the core energetic deficit in CNS cells provides a robust scientific realization of the traditional concept of *Rasayana* (rejuvenation and vitality promotion) at a cellular level.

### 4.2. Clinical Validation of Cognitive Improvement in MS

The neuroprotective and pro-myelinating effects of CNM-Au8 translate directly into quantifiable clinical benefits, particularly in cognitive domains. The Phase 2 VISIONARY-MS

trial in participants with stable relapsing MS provides compelling evidence.

Cognitive function in the trial was assessed using the **Symbol Digit Modality Test (SDMT)**, a highly sensitive and reliable measure of information processing speed and sustained attention widely used in MS research.<sup>7</sup> The long-term open-label extension (LTE) of the trial demonstrated that CNM-Au8 treatment yielded significant and clinically meaningful improvement in cognition ( $p<0.0001$ ) through 35 months from randomization.<sup>7</sup>

Specifically, the least-square mean difference for SDMT change versus the original randomization baseline at Week 144 was quantified at **+8.03** (\$95% CI: \$5.01\$ to \$11.0\$).<sup>7</sup> Furthermore, the REPAIR-MS and REPAIR-PD trials confirmed the metabolic basis of this efficacy, showing that 12 weeks of treatment resulted in a statistically significant average increase of \$0.589\$ (or +10.4%) in the mean brain  $\text{NAD}^+/\text{NADH}$  ratio across cohorts ( $p=0.037$ ).<sup>5</sup>

### **4.3. Linking Cognitive Gain to Structural Tissue Repair**

A hallmark of the CNM-Au8 research is the successful correlation of functional cognitive improvement with objective biological evidence of tissue repair, suggesting a fundamental reversal of pathology rather than mere symptomatic relief.

Analyses of the VISIONARY-MS LTE demonstrated that the clinically observed cognitive gains were consistent with improvements in structural and functional neurological markers.<sup>18</sup> Key findings included:

- **Anatomical Evidence:** MRI Diffusion Tensor Imaging (DTI) metrics, specifically Magnetization Transfer Ratio (MTR) and Axial Diffusivity (AD), confirmed improvements in the brain's neuronal structure consistent with **remyelination and neuronal repair**.<sup>18</sup>
- **Functional Evidence:** Multi-focal Visual Evoked Potential (mf-VEP) metrics, which track nerve signal transmission, confirmed functional improvements in the visual system and correlated strongly with cognitive improvements.<sup>18</sup>

This analysis established robust concordance: 98% of participants showing improved cognition (SDMT responders) also exhibited corresponding MRI improvements, and 91% of SDMT responders also demonstrated a VEP response.<sup>8</sup> This high level of correlation provides compelling evidence that the gold nanocrystal is acting as a genuine disease-modifying catalyst, actively promoting tissue repair and restoring function in chronic neurodegenerative disease.

Table 2 synthesizes the high-level clinical evidence for CNM-Au8, establishing the benchmark for targeted gold-based neurotherapeutic intervention.

Table 2: Modern Gold Nanomedicine: CNM-Au8 Clinical Cognitive and Metabolic Data

Trial/Cohort	Formulation	Primary Mechanism	Cognitive Assessment Tool / Endpoint	Quantified Cognitive/Metabolic Improvement (Long-Term)	Objective Biomarker Correlation
<b>REPAIR-M S/PD (Phase 2)</b>	CNM-Au8 (Gold Nanocrystals)	Catalytic NAD+/NADH Ratio Enhancement	Brain Energy Metabolites (P-MRS)	Significant increase in brain NAD+/NADH ratio (+10.4%, p=0.037) after 12 weeks <sup>5</sup>	Direct metabolic outcome measure
<b>VISIONARY -MS (Phase 2 LTE)</b>	CNM-Au8 (Gold Nanocrystals)	Neuroprotection, Remyelination	Symbol Digit Modality Test (SDMT)	Significant improvement through 35 months; LS mean difference \$+8.03\$ <sup>7</sup>	MRI DTI (MTR/AD) and mf-VEP confirmed structural repair correlating with SDMT gains (98% concordance) <sup>8</sup>

## V. Comparative Neurobiology, Safety, and Translational Outlook

The research into gold-based neurotherapeutics reveals a shared dependency on nano-scale delivery but a divergence in primary mechanisms and translational maturity.

### 5.1. Mechanistic Divergence and Efficacy Spectrum

Both the traditional system (*Swarna Bhasma*) and the modern system (CNM-Au8) rely on orally delivered gold nanoparticles that access the CNS.<sup>4</sup> However, their primary pharmacological roles differ:

1. **Traditional SB:** Demonstrated effects are rooted in generalized **antioxidant capacity**<sup>4</sup>, which is highly effective for managing acute deficits like sleep deprivation-induced cognitive impairment and anxiety.<sup>3</sup>
2. **Modern CNM-Au8:** Proven action is targeted **metabolic catalysis** of the NAD pathway<sup>16</sup>, leading to measurable structural tissue repair and functional cognitive recovery in chronic neurodegeneration.<sup>8</sup>

While the traditional poly-formulations (e.g., *Kumarabharana Rasa*) aim for a broad, systemic *Rasayana* effect<sup>1</sup>, CNM-Au8 is an engineered therapy designed for targeted disease modification in defined neurological patient populations, providing a focused, quantifiable therapeutic outcome.

## 5.2. Safety, Precision, and the Therapeutic Index

The analysis of gold nanomedicines highlights a critical reliance on dose precision, demonstrating that the therapeutic index for neuroactivity is narrow. While *Swarna Bhasma* is generally regarded as non-toxic and safe at the therapeutic doses tested in rat models<sup>9</sup>, studies indicate a clear dose-dependent profile.<sup>3</sup> Research in *Drosophila melanogaster* confirmed that moderate doses of SB were beneficial, whereas **higher doses induced overt neurotoxic effects**.<sup>3</sup>

Furthermore, investigations into the chronic effects of gold nanoparticles reveal potential for adverse neurobiological outcomes. One study noted that chronic oral administration of Au-NPs induced histopathological distortion, including shrunken, irregular Purkinje cells in the cerebellum, and that these changes were more dose-dependent than time-dependent.<sup>22</sup> Another study found that gold nanoparticles influenced the emotional state of mouse offspring exposed prenatally, leading to increased anxiety levels, although spatial orientation and memory were not affected.<sup>23</sup>

This evidence creates a paradox: gold nanoparticles can improve cognition and promote tissue repair (CNM-Au8, moderate SB doses) but also possess the potential to induce subtle neurotoxicity or affect emotional regulation if purity and dosage are not precisely controlled. This dependence on precision explains the favorable safety profile observed in CNM-Au8 clinical trials, which reported that treatment was well-tolerated with no serious adverse events attributed to the drug.<sup>17</sup> The high standards of analytical control over particle size and surface chemistry in engineered nanomedicines mitigate the risks associated with hitting the neurotoxic threshold, emphasizing that rigorous standardization is essential for reliable gold-based neurotherapeutic development.

## VI. Conclusions and Future Directions

Research confirms that effective gold-based formulations capable of yielding cognitive benefits exist well beyond the realm of *Suvarnaprashana*. These alternatives fall into two

distinct categories based on their evidence profile and mechanism:

1. **Traditional Poly-Formulations (e.g., Kumarabharana Rasa, Brahmi Vati Gold):** These preparations leverage the synergistic power of *Swarna Bhasma*'s preclinical antioxidant and anxiolytic properties alongside established herbal nootropics. However, the scientific verification of gold's incremental benefit in these complex blends is lacking. Future research must conduct randomized, comparative clinical trials assessing the cognitive outcomes of gold-infused formulations against their standard herbal counterparts to isolate and quantify the effect contributed by the gold component.
2. **Modern Catalytic Nanomedicine (CNM-Au8):** This system represents the highest level of evidence for gold-based neurotherapeutics, demonstrating that engineered gold nanocrystals can function as a specific metabolic catalyst. Clinical data confirms significant cognitive improvement linked to structural neuronal repair (remyelination) in MS patients, validating gold as a highly effective, disease-modifying agent when precisely manufactured and administered.

The overarching lesson from both traditional and modern systems is that the neuroactivity of gold nanoparticles is potent but highly sensitive to preparation and dose. Future translational efforts, whether refining traditional *Bhasmas* or advancing new engineered systems, must prioritize strict analytical control over particle size, purity, and dosing to maximize therapeutic efficacy and eliminate the risk of dose-dependent neurotoxicity.

## Works cited

1. a review on kumarabharana prasha: a novel ayurvedic electuary - ResearchGate, accessed October 7, 2025,  
[https://www.researchgate.net/publication/325930418\\_A REVIEW ON KUMARABHARANA PRASHA A NOVEL AYURVEDIC ELECTUARY](https://www.researchgate.net/publication/325930418_A REVIEW ON KUMARABHARANA PRASHA A NOVEL AYURVEDIC ELECTUARY)
2. Brahmi Vati Gold 25 Tabs - Unlock mental clarity in 5 days ..., accessed October 7, 2025, <https://paramanandayurveda.com/product/brahmi-vati-gold/>
3. Neuroprotective efficacy of swarna bhasma on sleep deprived induced cognitive impairment in rats - ResearchGate, accessed October 7, 2025,  
[https://www.researchgate.net/publication/324526802\\_Neuroprotective\\_efficacy\\_of\\_swarṇa\\_bhasma\\_on\\_sleep\\_deprived\\_induced\\_cognitive\\_impairment\\_in\\_rats](https://www.researchgate.net/publication/324526802_Neuroprotective_efficacy_of_swarṇa_bhasma_on_sleep_deprived_induced_cognitive_impairment_in_rats)
4. The Effect of Swarnaprashana on Mental Health and Well-being of Children: A Comprehensive Review, accessed October 7, 2025,  
<https://africanjournalofbiomedicalresearch.com/index.php/AJBR/article/download/17091/5847/13952>
5. Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials - PubMed Central, accessed October 7, 2025,  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC10717868/>
6. Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients - BioSpace, accessed October 7, 2025,

- <https://www.biospace.com/press-releases/clene-presents-new-clinical-data-at-ectrims-2025-meeting-demonstrating-cnm-au8-improves-brain-energy-metabolism-in-multiple-sclerosis-patients>
7. Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension, accessed October 7, 2025,  
<https://invest.clene.com/news-releases/news-release-details/clene-reports-significant-improvement-vision-and-cognition-cnm/>
  8. AAN 2025: Gains from CNM-Au8 in RRMS linked to nerve cell repair, accessed October 7, 2025,  
<https://multiplesclerosisnewstoday.com/news-posts/2025/04/11/aan-2025-gains-seen-cnm-au8-rrms-linked-nerve-cell-repair/>
  9. Physicochemical characterization of Suvarna Bhasma, its toxicity profiling in rat and behavioural assessment in zebrafish model - PubMed, accessed October 7, 2025, <https://pubmed.ncbi.nlm.nih.gov/31730889/>
  10. Exploratory studies on the therapeutic effects of Kumarabharana Rasa in the management of chronic tonsillitis among children at a tertiary care hospital of Karnataka, accessed October 7, 2025,  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC4738038/>
  11. Exploratory studies on the therapeutic effects of Kumarabharana Rasa in the management of chronic tonsillitis among children at a tertiary care hospital of Karnataka - PubMed, accessed October 7, 2025,  
<https://pubmed.ncbi.nlm.nih.gov/26870676/>
  12. a review on kumarabharana prasha: a novel ayurvedic electuary, accessed October 7, 2025, [https://ijrap.net/admin/php/uploads/2067\\_pdf.pdf](https://ijrap.net/admin/php/uploads/2067_pdf.pdf)
  13. Saraswatharishtam with Gold (Special): Excellent Tonic for Memory & Immunity Booster, accessed October 7, 2025,  
<https://ayurdhama.com/product/saraswatharishtam-with-gold-special-excellent-tonic-for-memory-immunity-booster/>
  14. Gold nanoparticles reverse brain deficits in multiple sclerosis, Parkinson's : Newsroom - UT Southwestern, Dallas, Texas, accessed October 7, 2025,  
<https://www.utsouthwestern.edu/newsroom/articles/year-2024/feb-gold-nanoparticles-brain-deficits.html>
  15. Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment, accessed October 7, 2025, <https://invest.clene.com/node/11461/pdf>
  16. Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease, accessed October 7, 2025,  
<https://invest.clene.com/news-releases/news-release-details/clene-presents-preclinical-data-supporting-cnm-au8r-treatment/>
  17. Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum, accessed October 7, 2025, <https://invest.clene.com/node/10241/pdf>
  18. Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session, accessed October 7, 2025,

<https://invest.clene.com/news-releases/news-release-details/clene-presents-evidence-remyelination-and-neuronal-repair-cnm/>

19. Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session, accessed October 7, 2025,  
<https://invest.clene.com/news-releases/news-release-details/clene-presents-evidence-remyelination-and-neuronal-repair-cnm>
20. Swarna Bhasma Benefits in Ayurveda: Detoxification, Immunity & Vitality - Truemeds, accessed October 7, 2025,  
<https://www.truemeds.in/ayurveda/brain-health/swarna-bhasma-134>
21. Toxicity Study of Swarna Bhasma, an Ayurvedic Medicine Containing Gold, in Wistar Rats, accessed October 7, 2025,  
<https://informaticsjournals.co.in/index.php/toxi/article/view/20507>
22. Assessment of the potential cerebellar toxicity of gold nanoparticles on the structure and function of adult male albino rats - Portland Press, accessed October 7, 2025,  
<https://portlandpress.com/bioscirep/article/43/8/BSR20222255/233337/Assessment-of-the-potential-cerebellar-toxicity-of>
23. Impact of Chronic Oral Administration of Gold Nanoparticles on Cognitive Abilities of Mice, accessed October 7, 2025,  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC10219544/>